The company didn’t share specific data for the molecule, gefurulimab, but said it hit all endpoints in the Phase III PREVAIL ...

AstraZeneca (NASDAQ:AZN) announced Thursday that gefurulimab, its experimental injectable for generalized myasthenia gravis, ...

AstraZeneca PLC (NASDAQ:AZN) is one of the Stocks With Huge Catalysts on the Horizon. On July 24, AstraZeneca PLC (NASDAQ:AZN ...

AstraZeneca (LSE:AZN) announced promising trial results for gefurulimab, a potential new treatment for generalized myasthenia ...

Myasthenia gravis, or MG, is "a chronic autoimmune neuromuscular disorder that causes muscle weakness and fatigue," says Hesterlee. It occurs "when a person’s immune system is essentially ...

Three patient outcomes were measured in this new study: time to onset of ocular-related myasthenia gravis, Activities of ...

With treatment, myasthenia gravis can generally be controlled. In fact, about 50 percent of people who have their thymus gland removed may experience long-lasting, complete remission of myasthenia ...

Myasthenia Gravis is further subdivided into the following types based on their signs and symptoms. Generalised Myasthenia Gravis- This occurs when weakness occurs in multiple groups of muscles.

Myasthenia gravis causes muscle weakness. Though the weakness can be seen in the eyes and face you may also get in fingers, arms, legs, chest and elsewhere. Your weakness can worsen if you do any ...

A 33-year-old woman was found to be HIV-infected and diagnosed with myasthenia gravis by a neurologist in 1999. She was treated with pyridostigmine (60 mg 5 times daily) but had a myasthenia ...

A REVIEW of myasthenia gravis was published in the Journal 1 in 1951, to bring the survey of the published reports up to the midyear. The present paper continues the survey of the subject to the cl ...

Myasthenia Gravis, Thymoma and Cryptococcal Meningitis Authors: Lewis P. Rowland, M.D., Cadvan O. Griffiths, M.D., and Elvin A. Kabat, Ph.D. Author Info & Affiliations Published September 16, 1965 ...